Xeris Pharmaceuticals ( (XERS) ) has issued an announcement.
On March 28, 2025, Xeris Biopharma Holdings announced significant changes to its board of directors. Ricki Fairley resigned due to other commitments, and John Schmid decided not to seek re-election at the 2025 Annual Meeting, leading to a reduction in board size to eight members. James Brady was appointed as a new director, bringing extensive experience from his previous roles at AstraZeneca, including as CFO of MedImmune. His appointment is expected to enhance the board’s expertise as Xeris continues to innovate and expand its market presence.
More about Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company dedicated to improving patient lives through the development and commercialization of innovative products across various therapies. The company offers three commercially available products: Recorlev® for endogenous Cushing’s syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis. Xeris is also advancing a pipeline of development programs, including XP-8121 for hypothyroidism, leveraging its technology platforms, XeriSol® and XeriJect®.
YTD Price Performance: 62.72%
Average Trading Volume: 2,499,406
Technical Sentiment Signal: Sell
Current Market Cap: $866.7M
Learn more about XERS stock on TipRanks’ Stock Analysis page.